TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15117040
Drug: Topical ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ciprofloxacin 0.3%
Study: 11201778
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin 0.3%
Study: 11400186
Drug: (R)‐carvedilol 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)‐carvedilol 12.5 mg
Study: 11400186
Drug: (S)‐carvedilol 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)‐carvedilol 12.5 mg
Study: 11400186
Drug: (R,S)‐carvedilol 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R,S)‐carvedilol 25 mg
Study: 9257784
Drug: mSRW (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: mSRW (high doses >20 microg of Amb a 1)
Study: 8292063
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dimetindene
Study: 8292063
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dimetindene
Study: 23991622
Drug: Prasugrel (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (30 mg loading dose before angiography, additional 30 mg at PCI if indicated)
Study: 21414048
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OIT) with gradual updosing to 800 mg of protein (5 peanuts/day) followed by 30-week maintenance
Study: 21414048
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OIT) with gradual updosing
Study: 18806534
Drug: Topical fentanyl
Normalized name: fentanyl Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fentanyl plus dexpanthenol
Study: 10995003
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (1.5 g/m2, 2.25 g/m2, or 3 g/m2 every 2 weeks for three doses)
Study: 10995003
Drug: Fludarabine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (25 mg/m2/day for 5 days every 4 weeks for six cycles)
Study: 10995003
Drug: Fludarabine followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine followed by high-dose cyclophosphamide
Study: 20549501
Drug: Meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 7.5 mg once daily
Study: 8981385
Drug: Scopolamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.5 mg i.v.)
Study: 3849459
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Pancreatin and Cimetidine
Study: 3849459
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (previous studies)
Study: 17012980
Drug: Adjunctive quetiapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive quetiapine (<400 mg/day)
Study: 16239629
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin therapy
Study: 16239629
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin therapy
Study: 8965152
Drug: Acetaminophen with
Normalized name: acetaminophen with codeine ORAL ELIXIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen with codeine (APAP/C)
Study: 1464159
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) treatment during intensive consolidation
Study: 1464159
Drug: Folate (F)
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate (F) levels during treatment
Study: 1464159
Drug: RBC MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC MTX and RBC F levels during maintenance therapy
Study: 31738483
Drug: Lower-target group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-target group (LDL cholesterol < 70 mg/dL)
Study: 31738483
Drug: Higher-target group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-target group (LDL cholesterol 90-110 mg/dL)
Study: 26084138
Drug: Tramadol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (1.5 mg/kg loading dose and patient-controlled analgesia for 1 day)
Study: 26084138
Drug: Paracetamol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1 g intravenously 30 min before the end of the operation and 1 g each day at 6‐h intervals)
Study: 18632258
Drug: Budesonide plus
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide plus formoterol (400 mcg and 24 mcg/day, respectively)
Study: 18632258
Drug: Budesonide (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (800 mcg/day)
Study: 11125148
Drug: Cholinesterase inhibitor
Normalized name: Acetylcholinesterase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitor physostigmine
Study: 9013229
Drug: Treatment according
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according to protocol
Study: 1575333
Drug: Propofol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.5 mg/kg and 1.0 mg/kg 3 min later)
Study: 1575333
Drug: Thiopental (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (5.0 mg/kg and 2.0 mg/kg 3 min later)
Study: 31939265
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) applied perineally, 3000 pulses weekly for four consecutive weeks, energy flux density 0.25 mJ/mm2, frequency 4 Hz
Study: 31939265
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with a non-functional handpiece
Study: 27526146
Drug: BioPQQ™ (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: BioPQQ™ (20 mg)
Study: 24429126
Drug: QVA149 (indacaterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 (indacaterol 110 μg and glycopyrronium 50 μg)
Study: 24429126
Drug: Glycopyrronium (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium (50 μg)
Study: 23558666
Drug: Tiotropium (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (18 μg)
Study: 19589894
Drug: Etoricoxib 30
Normalized name: Etoricoxib 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 30 mg
Study: 21905970
Drug: Etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg and 90 mg
Study: 1743317
Drug: 0.1‐mg Estraderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1‐mg Estraderm Patch worn for 7 days with 0.6 mL of ethanol injected on day 3
Study: 1743317
Drug: 0.1‐mg Estraderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1‐mg Estraderm Patch worn for 7 days without ethanol
Study: 6292957
Drug: Trimethoprim-polymyxin ophthalmic
Normalized name: polymyxin B / trimethoprim Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-polymyxin ophthalmic solution
Study: 6292957
Drug: Chloramphenicol ophthalmic
Normalized name: chloramphenicol ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol ophthalmic solution
Study: 31928864
Drug: Cerebellar rTMS
Normalized name: Sus scrofa cerebellum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebellar rTMS (10Hz, 250 pulse) - single treatment
Study: 31928864
Drug: Cerebellar rTMS
Normalized name: Sus scrofa cerebellum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebellar rTMS - daily for 3 days, twice-daily for 5 days
Study: 31928864
Drug: Sham stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham stimulation - twice-daily for 5 days
Study: 28626140
Drug: LCPUFA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCPUFA supplementation (docosahexaenoic acid (DHA) 300 mg/day, eicosapentaenoic acid (EPA) 100 mg/day, arachidonic acid (ARA) 120 mg/day)
Study: 18710719
Drug: Placebo (folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (folic acid tablets)
Study: 15985034
Drug: 4% hydroquinone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% hydroquinone cream (group A)
Study: 15985034
Drug: 4% hydroquinone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% hydroquinone, 0.05% tretinoin and 0.05% dexamethasone cream (group B)
Study: 11928798
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy for rectal cancer
Study: 2187603
Drug: Solution A
Normalized name: I.V. SOLUTION ADDITIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution A (168 mmol/L sugar, 326 mosm/kg)
Study: 2187603
Drug: Solution D
Normalized name: KIT, PATCH, MEDICATED AND SOLUTION DROPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution D (90 mmol/L sugar, 240 mosm/kg)
Study: 6103680
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate 10 to 30 mg per day
Study: 31236874
Drug: Treatment-related increases
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related increases in dietary restraint behaviors
Study: 26003406
Drug: Usual daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual daily activities (control group).
Study: 19174530
Drug: LC-MS/MS steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC-MS/MS steroid measurements
Study: 6148879
Drug: Propranolol, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 40 mg every 6 hours for 14 days
Study: 6148879
Drug: Nadolol, 80
Normalized name: Nadolol, 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol, 80 mg each morning for 14 days
Study: 27146108
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (Crinone 8% vaginal gel, 90 mg per day) for 14 days in CC/IUI cycles
Study: 27146108
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (Crinone 8% vaginal gel, 90 mg per day) for 14 days in Gn/IUI cycles
Study: 27146108
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CC/IUI cycles without luteal-phase support)
Study: 22348650
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behaviour therapy (ICBT) for 10 weeks
Study: 24244406
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behaviour therapy (GCBT) for 10 weeks
Study: 18405149
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and moxibustion added to routine treatment, once daily for 10 days.
Study: 16870951
Drug: α-adrenergic antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: α-adrenergic antagonists
Study: 12573204
Drug: OM-85 BV
Normalized name: OM-85 BV
DrugBank: OM85 (DB16533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM-85 BV (3.5 mg)
Study: 1736694
Drug: Epidural clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural clonidine 400 micrograms bolus followed by 40 micrograms/h infusion
Study: 1736694
Drug: Epidural clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural clonidine 800 micrograms bolus followed by 40 micrograms/h infusion
Study: 1736694
Drug: Epidural clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural clonidine (both doses) after bupivacaine
Study: 31085043
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Osimertinib + Bevacizumab)
Study: 22372795
Drug: OMP 20
Normalized name: OMP-54F28
DrugBank: Ipafricept (DB15045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMP 20 mg
Study: 20928987
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (liquid iron and vitamins A and D)
Study: 17993007
Drug: Xinnaoxin capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinnaoxin capsules
Study: 15644006
Drug: 5 ml.h(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml.h(‐1) ropivacaine 0.2% (study group, n = 21)
Study: 15644006
Drug: 5 ml.h(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml.h(‐1) saline (control group, n = 21)
Study: 8872628
Drug: 700-ml infusion
Normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700-ml infusion of autologous erythrocytes (42% hematocrit)
Study: 1732596
Drug: Intravesical epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical epirubicin administration
Study: 30705097
Drug: Pegylated-asparaginase, intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated-asparaginase, intravenously at a dose of 2,500 IU/m2 on days 12 and 26
Study: 28038881
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract plus diclofenac tablet
Study: 28038881
Drug: Diclofenac tablet
Normalized name: diclofenac Oral Tablet
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac tablet alone
Study: 12598214
Drug: In-laboratory determined
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-laboratory determined optimal pressure CPAP treatment
Study: 10413395
Drug: General Internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Internal Medicine
Study: 8585108
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg once daily
Study: 28655025
Drug: CAM2038 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAM2038 24 mg
Study: 28655025
Drug: CAM2038 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAM2038 32 mg
Study: 19785510
Drug: Atomoxetine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (0.5 to 1.2 mg/kg/day, uptitrated after two weeks)
Study: 16923216
Drug: Freshly chopped
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Freshly chopped chilli blend (30 g/d; 55% cayenne chilli)
Study: 8030582
Drug: Mepiphylline (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepiphylline (8 mg/kg/day divided in 3 doses for 10 days)
Study: 8030582
Drug: Mepiphylline (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepiphylline (8 mg/kg/day)
Study: 233825
Drug: Wheat fiber
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat fiber (36 g) added to diet for 3 weeks
Study: 19583677
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg (oral dose)
Study: 26706833
Drug: Exemestane therapy
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane therapy
Study: 11032585
Drug: Tamoxifen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen therapy
Study: 15534410
Drug: OP‐1 Putty
Approvals — FDA: no, EMA: no, PMDA: no
Description: OP‐1 Putty (3.5 mg of OP‐1 per side)
Study: 11535566
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (10 mg once a day)
Study: 11535566
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid plus transdermal GTN
Study: 11535566
Drug: Transdermal GTN
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal GTN plus placebo
Study: 7845167
Drug: Omeprazole 3x40
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 3x40 mg + Amoxicillin 3x750 mg for 14 days
Study: 7845167
Drug: Classical triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical triple therapy containing bismuth and two antibiotics
Study: 25708419
Drug: Probiotic preparation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic preparation administered twice a day from ICU admission until 7 days or discharge from ICU.
Study: 25708419
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no probiotics administered).
Study: 20644484
Drug: 0.8 g
Normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g MnCl2 (n = 11)
Study: 20644484
Drug: 1.6 g
Normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g MnCl2 (n = 9)
Study: 20644484
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses (0.8 g and 1.6 g MnCl2)
Study: 3067116
Drug: Tianeptine (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine (37.5 mg per day)
Study: 380915
Drug: Amitriptyline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75 mg per day)
Study: 29691148
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blocker (ARB) - valsartan
Study: 29691148
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (ACEI) - ramipril
Study: 28533054
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine (2+1 doses at 3½-5-11 months or 6-8-11 months)
Study: 28533054
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine (3+1 doses at ages 2½-3½-5-11 months)
Study: 28533054
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine (2 catch-up doses administered 2 months apart)
Study: 23846749
Drug: Hydromorphone titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone titration protocol (0.5 mg intravenous hydromorphone initially, with a second dose of 0.5 mg if requested)
Study: 23846749
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (any dose of any intravenous opioid)
Study: 21952034
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg vitamin B12 pill taken daily and routine PACAM food
Study: 21952034
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill and milk-PACAM food fortified to provide 1 mg of vitamin B12
Study: 21952034
Drug: Routine PACAM
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine PACAM food and placebo pill
Study: 18978634
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication management plus relapse prevention cognitive-behavioral therapy (MM+CBT)
Study: 18978634
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication management (MM)
Study: 12729423
Drug: 10-day oral
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day oral doxycycline
Study: 12729423
Drug: 20-day oral
Normalized name: ferrous fumarate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-day oral doxycycline
Study: 12729423
Drug: Doxycycline +
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline + ceftriaxone (single intravenous dose)
Study: 10934099
Drug: Inhaled PGE(2)
Normalized name: PGE-1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled PGE(2) (100 microgram)
Study: 1525104
Drug: gemeprost alone
Normalized name: gemeprost
DrugBank: Gemeprost (DB08964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemeprost alone (1 mg every 6 h up to three doses)
Study: 1525104
Drug: mifepristone (200‐600
Approvals — FDA: no, EMA: no, PMDA: no
Description: mifepristone (200‐600 mg) followed 48 h later by a single dose of gemeprost (1 mg)
Study: 28982101
Drug: Misoprostol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (2 tablets, 400 µg administered vaginally 12 hours before hysteroscopy)
Study: 28982101
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 placebo tablets administered)
Study: 26851398
Drug: Rolapitant (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolapitant (180 mg)
Study: 22351940
Drug: ASP2151 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP2151 (100 mg daily for 3 days)
Study: 22351940
Drug: ASP2151 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP2151 (200 mg daily for 3 days)
Study: 22351940
Drug: ASP2151 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP2151 (400 mg daily for 3 days)
Study: 22351940
Drug: ASP2151 (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP2151 (1200 mg as a single dose)
Study: 27129009
Drug: Valacyclovir (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (500 mg twice daily for 3 days)
Study: 15907554
Drug: Caspofungin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (50 mg/day after a 70 mg loading dose)
Study: 15907554
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (0.6-1.0 mg/kg/day)
Study: 14753637
Drug: Midazolam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (mean 12.5 mg)
Study: 14753637
Drug: Diazepam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (mean 28.1 mg)
Study: 11573659
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia with propofol and alfentanil
Study: 7457638
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg of caffeine
Study: 28722271
Drug: Liraglutide (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (0.6 to 1.8 mg over 24 weeks)
Study: 27787672
Drug: Methylphenidate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.3 and 0.6 mg/kg)
Study: 22982353
Drug: Contraceptive vaginal
Normalized name: VCF 4% Contraceptive Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive vaginal ring (CVR) delivering 150/15 μg Nestorone®/ethinyl estradiol (EE) daily